Biogen CEO: Tysabri to reach $1B in 2008

Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street Journal reports.

Tysabri was recalled in 2005 after three patients developed a rare brain infection and two died. FDA let the drug back on the market the next year under a monitoring program. Just two years later, Tysabri is expected to surpass $1 billion in annual sales, according to Biogen CEO James Mullen. First-quarter sales were $160 million, and second-quarter numbers will be announced tomorrow.

- read the WSJ article

Related Articles:
No new PML cases for Tysabri
Watchdog endorses use of Tysabri for severe MS
After reintroduction, Tysabri builds patient base
FDA allows Tysabri back on market